5. Coronavirus disease (COVID-19)

Coronavirus disease 2019 (COVID‑19) is caused by the SARS-CoV-2 virus, which infects the respiratory tract and is transmitted human to human primarily through respiratory droplets and aerosols. Documented transmission has also occurred through direct contact and rarely fomites (objects or materials that can carry infection).

The symptoms of COVID 19 range widely from asymptomatic infection or from a mild to severe respiratory tract infection and pneumonia, which can lead to severe inflammatory disease and respiratory failure. The most common symptoms of COVID-19 are like those of other common respiratory illnesses and include a new or worsening dry cough, sneezing and rhinorrhoea or nasal congestion, fever, sore throat, shortness of breath and fatigue. Unlike other respiratory viral infections, COVID 19 is frequently associated with a temporary loss of smell or altered sense of taste. Some cases have reported gastrointestinal symptoms including nausea, diarrhoea, vomiting and abdominal pain, headache, muscle aches, malaise, chest pain, joint pain, and confusion or irritability; these symptoms almost always occur with one or more of the common symptoms. For most cases COVID 19 is a mild disease, but some can develop more severe disease or exacerbation of comorbidities. As for influenza and other respiratory viruses, some of those with laboratory-confirmed infection remain asymptomatic.

In the early stages, it is difficult to distinguish COVID 19 symptoms from other common viral infections. The most reliable common diagnostic test has been detection of viral mRNA from a nasopharyngeal swab, using PCR assay and rapid antigen tests (RATs).

The incubation period is typically around two to five days (up to 14 days). Individuals may be infectious from up to two days before becoming symptomatic.[4] Unlike previous coronavirus outbreaks (SARS and MERS), transmission of SARS-CoV-2 can also occur before the onset of symptoms or from asymptomatic individuals.[5] Viral loads and infectiousness are highest immediately after symptom onset, and most transmission occurs in household settings.[6, 7]

It is currently unclear what or for how long protection is provided from previous infection with SARS-CoV-2. Early in the pandemic, neutralising antibodies were shown to remain relatively stable between eight to 11 months after primary infection.[8, 9] Reinfection, including in vaccinated individuals, can occur. Frequently, reinfection is due to exposure to different variants of SARS-CoV-2 that are better able to evade the immune response and when inadequately matched neutralising antibody immunity has waned. The risk of reinfection is less in vaccinated individuals, and hybrid immunity, from both infection and vaccine, reduces the risk of COVID-19 hospitalisation.[10, 11] The degree of protection remains unclear and is likely to be highly variable depending on individual risk for severe disease, so continued COVID-19 vaccination post infection is recommended as per the Schedule to maintain neutralising antibody levels, particularly for high-risk groups.

Overall, the incidence of severe or fatal disease in children is significantly lower than in adults, with fewer hospitalisations and shorter hospital stays. The incidence is less for the Omicron variants than the previous variants.[12,13] Children at highest risk of more severe disease are predominantly those living with pre-existing significant health conditions and those living in areas with highest levels of deprivation.[13] Pre-existing conditions in children associated with increased risk from COVID-19 include obesity, diabetes, cardiac and pulmonary diseases, immune disorders, metabolic disease, cancer, neurological, neurodevelopmental (in particular, Down syndrome [trisomy 21]) and neuromuscular conditions.[14, 15] These risk factors are prevalent in New Zealand children, particularly for some Māori and Pacific children.[16, 17]

Paediatric multisystem inflammatory syndrome

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS or MIS-C) is a rare, delayed complication of COVID-19 following largely asymptomatic SARS-CoV-2 infection in children and adolescents.[18, 19] Surveillance in England has found that, despite the very high numbers of COVID-19 cases associated with the Omicron variants, the risk of PIMS-TS is extremely low due to most children having immunity to SARS-CoV-2 through previous infection and vaccination.[13]

Risk factors for severe disease include older age, male, smoking,[20] obesity and chronic medical conditions, including diabetes,[21] cancer, chronic respiratory disease, cardiovascular disease, chronic kidney disease, hypertension, immunocompromise[22] and pregnancy (see below). Increased incidence is well documented in some ethnic groups but seems primarily related to prevalence of the risk factors listed above. Increasing age is the most important risk factor for severe disease, due to declining immune function and high prevalence of comorbidities. The highest risk group for severe illness and mortality is those aged over 70 years[23], although Māori and Pacific populations experience age-related risk at a younger age than other ethnicities.

Pregnancy

Pregnancy can increase the risk of severe disease and death compared with age-matched non-pregnant women.[24,25,26,27] While the absolute risk of severe outcomes during pregnancy is low compared with absolute risk due to advanced age, adverse pregnancy and perinatal outcomes, including acute renal failure, acute respiratory distress, mechanical ventilation, ICU admission, and preterm labour with preterm delivery, occur at a higher rate in pregnant people with COVID-19 during delivery hospitalisations than those without.[28] A healthcare database review including almost three million pregnant people found that although the risk was considerably lower than during the Delta predominant period, those with Omicron infection during hospital delivery were five times more likely to die during delivery than those without COVID-19. During the Omicron period, the risk for all adverse outcomes was significantly higher at delivery for those with COVID-19 than those without, except for thromboembolic disease and acute cardiac events (comparison of 26,053 with Omicron and 1,270,490 without COVID-19).[28] Unvaccinated pregnant people are at four times the risk of hospitalisation with moderate to severe COVID-19 than those who had received three doses of vaccine.[29] One international study found that the risk for referral to ICU or death was over 20 times higher for unvaccinated pregnant women with Omicron COVID-19.[30] Obesity, hypertension, asthma, autoimmune disease, diabetes and older age are also associated with severe COVID‑19 in pregnancy and postpartum.[31]

Infants born to those with COVID‑19 are at increased risk of preterm birth, particularly due to maternal COVID-19 severity leading to early induction, and neonatal ICU admission.[25, 31] Early studies do not suggest intrauterine transmission, but transmission during birth has been shown in around 3 percent of neonates.[32] Most neonatal infections are asymptomatic or mild, but around 12 percent experience severe disease with dyspnoea and fever as the most commonly reported signs.[33]

Post-acute COVID-19 sequelae or commonly called ‘long COVID’ is characterised by persistent symptoms lasting for more than three months and appears to affect around 10 percent of those infected, particularly those with at least five symptoms in the first week of illness.[34, 35,36] Post-acute manifestations include cardiovascular, pulmonary and neurological effects, including chronic fatigue, dyspnoea, specific organ dysfunction and depression.[37]

Long COVID-19 is not well described in children, and although WHO formally agreed an international clinical case definition in February 2023, it was very broad.[38] In the UK in 2023, according to national statistics, the difference in prevalence of the most common persistent symptoms of long COVID-19 in children was 0.2 percent in 2-11 year olds and 1.0 percent in 12-16 year-olds between cases and controls.[13] Unfortunately, the broadly inclusive criteria for post-COVID-19 conditions fail to identify children who genuinely experience adverse complications of SARS-CoV-2 infection, such as chronic fatigue, respiratory compromise and cognitive difficulties.[13]

For further information see the Health NZ webpage Long COVID.

SARS-CoV-2 was first identified in January 2020 following clusters of distinctive pneumonia cases observed in Wuhan, China during December 2019. This virus has genetic and clinical similarity to the coronavirus causing the severe acute respiratory syndrome (SARS) epidemic from 2002 to 2004. A public health emergency of international concern (PHEIC) was announced in late January 2020. By the time the COVID‑19 pandemic was declared by the World Health Organization (WHO) on 11 March 2020, there were 118,000 reported COVID‑19 cases and 4,291 associated deaths in 114 countries. The global death toll surpassed one million by late September 2020. Case numbers and death continued to increase, with a rapid peak in cases at the end of December 2021 due to the more infectious omicron variant. As of 8 November 2022, WHO reported over 6.5 million cumulative COVID-19 deaths.

See the WHO Coronavirus Disease (COVID‑19) Dashboard for the latest official data. Actual rates are expected to be considerably higher than officially reported rates, especially since milder infections may not be reported.

The infection-fatality rate, while still high particularly in the older age groups, has reduced since the start of the pandemic, partly due to changes in the prevalent variants but also due to public health measures that include vaccination, improved clinical recognition and management and the use of therapies of demonstrated value, such as dexamethasone and antiviral medications such as nirmatrelvir with ritonavir, and molnupiravir.

The use of vaccines has reduced the global burden of COVID‑19 significantly. The first phase I clinical trial for a COVID‑19 vaccine commenced in March 2020 and the first public vaccination dose was administered in the United Kingdom on 8 December 2020. By late 2022, 11 COVID-19 vaccines had been granted emergency use listing or approval by the WHO.

In May 2023, the WHO declared an end to the PHEIC and moved forward to update its Strategic Preparedness and Response plan for 2023-2025 to transition from the emergency response to longer-term sustained COVID-19 protection, control and management.[39]

The first case of COVID‑19 was reported in New Zealand on 28 February 2020. Border restrictions were implemented on 16 March 2020 as cases numbers increased and clusters of transmission were identified. On 25 March 2020, New Zealand entered a nationwide lockdown (‘Alert level four’). With rapid contact tracing and the public health COVID-19 protection framework, the spread of SARS-CoV-2 was restricted during 2020 and 2021. Only 19 percent of the introductions of virus in 2020 resulted in ongoing transmission or more than one additional case.[40] Prior to the outbreak of the Delta variant in August 2021, most of the reported cases during 2021 were imported from overseas (over 95 percent from 1 January to 9 August 2021).

From 16 August 2021, the number of cases in New Zealand began to increase sharply due initially to the highly infectious Delta variant. From January 2022, when the more infectious Omicron variant entered the community, case numbers rose sharply but at this stage around 90 percent of the population aged from 12 years had been vaccinated with at least two doses of COVID-19 vaccine. In late February 2023, almost three years after the first reported case, there were over 2.2 million cases recorded, over 26,000 hospitalisations, and 711 ICU admissions for COVID-19. There were 1,599 deaths coded with COVID-19 as the underlying cause, and the vast majority (96 percent) were aged over 59 years.

The COVID-19 Mortality Report in published September 2022 found that although COVID-19-attributed mortality was highest in older age groups, based on age-adjusted estimates, the risk of mortality for those aged under 60 years was 3.7 times higher for those Māori and 3.9 times higher for those of Pacific ethnicities than of European and Other ethnicities.[41] Comorbidity in those under the age of 60 years significantly increased the risk of mortality by 78 times, and explained 59 percent of the increased risk for Māori and 69 percent for Pacific ethnicities. Vaccination was shown to have a strong protective effect: after adjusting for age, sex, comorbidities and vaccination status (>2 doses), mortality risk was lowered but still 1.7 times higher in Māori and 1.9 times higher for Pacific compared with European/Other ethnicities.[41]

Emergence of new variants is monitored in New Zealand by ESR through whole genome sequencing of specimens taken from hospitalised cases and wastewater sampling. For current details on case demographics see COVID-19: Data and statistics and for the mortality report see COVID-19 Mortality in Aotearoa New Zealand: Inequities in Risk.

Clinical trials for COVID‑19 vaccine candidates began shortly after the pandemic was announced in March 2020. Between October to December 2020, the New Zealand Government signed advanced purchase agreements for four vaccine candidates, with purchase dependent on approval for use from the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). This is an ongoing process and, therefore, the availability and eligibility for these different vaccines may change.

Medsafe continues to review for each COVID-19 vaccine candidate, examining clinical trial and post-marketing surveillance data. Provisional consent imposes conditions on these vaccines to restrict their use by health professionals according to the available data at time of approval. This approval status allows New Zealanders early access to medicines with significant unmet clinical need under the Medicines Act.

Funded vaccines

The mRNA-CV, Comirnaty, consists of messenger ribonucleic acid (mRNA) encoding the full-length spike glycoprotein of the SARS-CoV-2 virus, inside a lipid nanoparticle. The spike protein mRNA has an adjuvant effect, so no additional adjuvant is included. The original version was designated BNT162b2 in clinical trials conducted by Pfizer and BioNTech. This mRNA vaccine delivers the instructions for human cells to build the viral antigen, SARS-CoV-2 spike protein. The mRNA is temporarily protected from degradation by the lipid nanoparticle that also facilitates fusion with the recipient’s cell wall.[42,43]

The adjuvanted recombinant COVID-19 vaccine (abbreviation rCV), Nuvaxovid, contains recombinant SARS-CoV-2 spike protein in a stabilised prefusion conformation. The spike protein is produced by an insect cell-line that has been infected with an insect baculovirus expressing SARS-CoV-2 spike protein genes. Together, the purified spike proteins and the adjuvant matrix are formed into immunogenic nanoparticles. The proprietary adjuvant (Matrix-M) contains two purified saponin fractions from Quillaja saponaria (soapbark tree) which enhances the innate immune response and activates the production of neutralising antibodies and T and B cell immunity. The vaccine was designated NVX-2373 in clinical trials conducted by Novavax and is sponsored in New Zealand by Biocelect. 

This section of the COVID-19 chapter reflects the development of the COVID-19 vaccines and the changing behaviour and variants of the SARS-CoV-2 infection during the COVID-19 pandemic. Further data is emerging. There is much heterogeneity in the immunity of different populations, many people have hybrid immunity to the wild-type infection as well as a range of booster doses, which make effectiveness measures challenging. Overall, COVID-19 vaccines continue to perform very well against severe disease and mortality, and in the short term can help to prevent symptomatic illness and infection.

mRNA COVID 19 vaccine – Comirnaty (Pfizer/BioNTech)

Immunogenicity

Compared with convalescent sera from those who had SARS-CoV-2 infection (original variant), the only group with lower antibody responses were older people (aged 55 – 85 years) but they had higher average neutralising antibody levels.[44] Clinical studies continued to assess immunogenicity in each age group in which the vaccines were used.[45,46,47] As SARS-CoV-2 variants evolved to become more immune evasive, higher levels of neutralising antibody were required to prevent infection. This was particularly evident in older people and those with comorbidities that affected the immune response. This was circumvented by offering booster doses and adapting the vaccine to better match circulating variants (ie bivalent and XBB.1.5 vaccines).

Efficacy – clinical trial data

Early in the pandemic, efficacy studies were straightforward as most individuals were naïve of SARS-CoV-2 vaccine. Efficacy of mRNA-CV 30 µg (BNT162b2) was first assessed during 2020 in the phase III component of a large, clinical trial. A total of 43,448 participants aged 16–85 years across six countries were randomised to receive vaccine or saline placebo, with a primary series of two doses given 21 days apart.[48] Interim data, based on the early SARS-CoV-2 variants, indicated a very high efficacy against symptomatic PCR-confirmed COVID-19 of 94.8 percent (95% CI: 89.8–97.6 percent) and consistent across all subgroups (defined by age, sex, race, ethnicity, baseline BMI and presence of co-existing conditions).[48] Efficacy in younger age groups was also high. For adolescents aged 12-15 years vaccinated with two doses of mRNA-CV (30 µg) efficacy of 100 percent (95% CI 75.3–100) was observed against symptomatic COVID-19 in 2020/2021.[45] A lower dose vaccine, mRNA-CV (10 µg) showed efficacy of 90.7 percent (95% CI 67.7–98.3) against symptomatic COVID-19 from seven days after dose two in 1,305 children aged 5–11 years.[46] Due to few cases in young children aged under 5 years, efficacy of mRNA-CV (3µg) was less well established. Combined for children aged 6-23 months and 2-4 years, vaccine efficacy of 80.4 percent (14.1–96.7 percent) was reported during a period of Omicron prevalence in the US.[47,49]

As the pandemic progressed, more hybrid immunity (with infection and vaccination) developed making placebo-controlled efficacy trials obsolete.

Effectiveness of primary course – real-world experience

At the start of the COVID-19 immunisation programmes in late 2020/early 2021, mRNA-CV (30 µg) was highly effective at preventing severe COVID-19 and COVID-19-related death, in line with efficacy observed during clinical trials.[50]

As the Delta variant emerged from mid-2021, effectiveness against symptomatic COVID-19 reduced (ranging from around 78–93 percent),[51] but the vaccine remained highly effective against hospitalisation (73–94 percent), severe disease and death (80-97 percent) in a range of groups in the UK.[52] With time following the two-dose primary series, the waning antibody levels were less effective against the Omicron variant and booster doses were required to help prevent symptomatic infection and reinfection (see below).

Vaccination with mRNA-CV in pregnancy reduces the risk of severe COVID-19 and provides passive immunity to the infant for the first few months of life.[53,54,55] During Delta, systematic review showed 70 percent reduction in SARS-CoV-2 infection in infants of vaccinated mothers for up to 6 months; vaccine effectiveness was much lower for omicron variants and the numbers of infants infected were very low.[56,57,58]

Adjuvanted recombinant COVID-19 vaccine – Nuvaxovid (Novavax)

Immunogenicity

Like that seen with mRNA vaccines, two doses of rCV induce a robust neutralising antibody immune response in adults across all ages 18-59 years and ages 60-84 years. The older participants had lower antibody titres of anti-spike protein IgG or wild-type neutralising antibody than the younger group. In clinical trials conducted during 2020 and early 2021 in the US and Australia, two doses of adjuvanted rCV were immunogenic in adults aged 18–59 years and 60–84 years.

Coadministration with influenza vaccine was investigated in a small phase I/II sub-study in UK hospitals. Around 400 participants were randomised to receive rCV and inactivated quadrivalent influenza vaccine for those aged 18–64 years or adjuvanted trivalent influenza vaccine for those aged 65 years or over, or rCV alone. Immunogenicity showed no change in the response to influenza vaccine but a reduction in antibody response to SARS-CoV-2. There was no difference in the seroconversion rates. Although the anti-spike protein IgG responses were 0.6-fold lower in the groups that received both vaccines, when post-hoc analysis of efficacy was considered, this reduction was not suggested to be clinically meaningful and in the younger age group, the anti-spike antibody levels were three-fold greater than found in convalescent serum.[59]

Efficacy – clinical trial

Data from two phase III clinical trials of adjuvanted rCV gave overall vaccine efficacy of 90 percent (95% CI 82.9-94.6 in PREVENT-19 study in US/Mexico and 80.2-94.6 percent in UK trial) against symptomatic COVID-19 from at least seven days after dose two.[60, 61] By age group, in approximately 10,000 vaccinated and placebo participants in the UK (randomised 1:1), vaccine efficacy against COVID-19 in those aged 18-64 years was 89.8 percent (79.7-95.5) versus 88.9 percent (20.2-99.7) in approximately 4,000 participants aged 65– 84 years.[61] In a subgroup of approximately 6,000 participants with coexisting illness, vaccine efficacy was 90.9 (70.4-97.2).[61] These clinical trials were conducted during late 2020 and early 2021, against predominantly Alpha not Delta or Omicron variants.

Following the completion of the placebo-controlled portion of a phase III clinical trial in the UK, vaccine efficacy of 82.7 percent (95% CI 73.3–88.8 percent) against COVID-19 was reported from 7 days to up to 7.5 months (median 4.5 months) after vaccination with rCV (24 cases vaccinated and 134 cases who received placebo out of 13,989 participants). Vaccine efficacy against severe COVID-19 was 100 percent (17.9–100 percent). Protection gradually decreased after 6 months indicating a need for a booster dose.[62]

Duration of immunity and additional doses

A decline in vaccine effectiveness was observed after the primary course against SARS-CoV-2 infection and mild disease, particularly with emerging Omicron variants, but protection against severe disease has been maintained and enhanced with the use of additional doses for around 6–9 months, at least.[63,64] It is unclear how long-lived immunity is following immunisation or natural infection. Many people now have hybrid immunity from both vaccination and infection. 

Although neutralising antibody levels wane,[65] and lower levels are less effective against the emerging variants such as Omicron lineages, T cell responses and memory are maintained in vaccine recipients (for mRNA-CV and rCV),[66,67] and this is likely to correspond to the observed the rate of disease being reduced. The greatest waning in immunity is observed in those aged over 65 years and those aged 40–64 years with underlying medical conditions compared with healthy adults.[68]

Across all age groups, at least three exposures to SARS-CoV-2 spike protein through vaccination and infection (hybrid immunity), provide significant protection against Omicron-associated hospitalisation and death. Further doses help to maintain a high level of immunity in elderly adults, particularly if they have exposed through infection previous. A Canadian cohort study of people with previous exposure to Omicron (BA.1 and BA.2 predominance) estimated protection at one to two months post vaccination to be 96 percent (95% CI 92-98) after a fourth dose of vaccine.[69]

Booster dose programmes were accelerated following the emergence of the Omicron variant from late 2021, including in New Zealand. Variant specific vaccines, including Omicron variant vaccines (eg BA.4/5 and XBB.1.5), are being used as additional doses to enhance protection against more immune-evasive omicron variants.[67,70]

mRNA COVID-19 vaccine – additional doses 

A range of cohort studies in the US has demonstrated a relative improvement in effectiveness of booster doses against severe COVID-19, especially for previously well-vaccinated older adults, when bivalent mRNA-CV was given.[71,72,73] Due to varying exposures to SARS-CoV-2 variants, timing since vaccine doses and in different populations, comparison between these studies is not possible and they did not provide evidence comparing monovalent original vaccine with the bivalent one.

Data from the Netherlands during October 2023 to January 2024 estimated effectiveness of the XBB.1.5 mRNA-CV (30 µg) vaccine to be around 41 percent against Omicron infection for those aged 18-59 years and 50 percent for ages 60-85 years who had received at least one previous booster.[74]  Earlier data, from October 2023 to December 2023 in the Netherlands, found XBB.1.5 mRNA-CV (30 µg) vaccine to be around 70 percent effective against hospitalisation and ICU admission (95% CI 67-74 percent and 42-88 percent, respectively) within the first two months of vaccination in adults aged 60 years and over.[75] In the US, the overall VE against symptomatic infection was 58 percent (48-65 percent) up to 59 days after vaccination and 49 percent (36-58 percent from 60-119 days after vaccination).[76] Since the XBB.1.5 vaccine formulations were created, Omicron variants have evolved but the vaccines are still demonstrating effectiveness against symptomatic disease and inducing a good neutralising antibody response against these newer variants, including BA.2.86 and JN.1.[76,77]

Adjuvanted recombinant COVID-19 vaccine – additional dose 

Immunogenicity of homologous booster doses of rCV, evaluated during a secondary analysis of a phase II clinical trial, showed that antibody levels induced by the booster dose in healthy adults were higher than levels associated with efficacy in the primary response phase III trials.[65] In the phase II clinical trial, conducted in the US and Australia, a single booster dose was given approximately six months after two-dose primary course of rCV to 105 healthy adults aged 18 to 84 years. Immune responses at 28 days post booster (day 217) were compared with those at 14 days post dose two (day 35). Serum IgG GMTs increased 4.7-fold from day 35 to day 217 against ancestral SARS-CoV-2, and 4.1-fold in the neutralisation assay. Increases in functional ACE2 receptor binding inhibition were also observed from day 189 to day 217 (pre and post booster) against various variants, including a 24-fold increase against Delta and 20-fold increase against Omicron. Anti-spike IgG activity also showed improved titres against a range of variants, including 92.5-fold increase against Delta and 73.5-fold increase against Omicron.[65]

mRNA COVID 19 vaccines – Comirnaty (3 µg, 10 µg and 30 µg)

These vaccines require storage at ultra-low temperatures (-90°C to -60°C) and at this temperature has a shelf-life of 18 months. Store unopened vials at +2°C to 8°C for up to 10 weeks within the 18 months shelf-life. Do not freeze.

Transport according to the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017 (2nd edition).

It is recommended that each vaccine is prepared as needed, always stored in the fridge and, where practical, doses are drawn up as required.

For single dose vials, store at +2°C to 8°C.

Store punctured multi-dose vials at +2°C to 30°C for a maximum of 12 hours, or store vaccine drawn-up in syringe for a maximum of six hours at +2°C to 30°C. Discard any vaccine exceeding these times, accordingly. For further details, see also the IMAC COVID-19 information and factsheets available from immune.org.nz.

For those that require dilution prior to use (see Table 5.1): once an undiluted vial is taken out of the refrigerator, allow a few minutes for the vaccine to reach room temperature prior to dilution. Store diluted vaccine in vials at +2°C to 8°C for a maximum of 12 hours, or store vaccine drawn-up in syringe for a maximum of six hours at +2°C to 30°C. Discard any vaccine exceeding these times, accordingly.

Adjuvanted recombinant COVID-19 vaccine – Nuvaxovid (Novavax)

Transport and store according to the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017 (2nd edition).

Store at +2°C to +8°C. Do not freeze. Protect vials from light. Unopened vials (with blue cap) have a shelf-life of up to six months. Opened vials should be used within 12 hours of first use. Vaccines should ideally be used within an hour of being drawn up. The maximum time the vaccine can be stored in a syringe is six hours when stored at +2°C to 25°C, and before the vial 12-hour expiry is reached, whichever is soonest. To ensure optimum use, in New Zealand, the vaccine is recommended to be always stored in the fridge and, where practical, doses are drawn up as required.

For further details, see also the IMAC COVID-19 information and factsheets available from immune.org.nz.

mRNA COVID‑19 vaccine – Comirnaty (Pfizer/BioNTech)

XBB.1.5 mRNA-CV (30 µg) for ages from 12 years (grey caps)

Individuals from the age of 12 years who have not previously received any doses of COVID-19 vaccine are recommended to receive a single dose of mRNA-CV (30 µg). For additional primary doses for severely immunocompromised, see section 5.5.3.

All individuals aged from 16 years can be offered a single dose after receiving a primary dose(s) of any COVID-19 vaccine, at least three months later. See section 5.5.4 for additional dose recommendations.

Individuals who have started but not completed a primary course.

Individuals aged 12 years and over who have started but not completed a primary course of any COVID-19 vaccine, including original mRNA-CV (30 µg), and have received no additional doses are can be offered a dose of XBB.1.5 mRNA-CV (30 µg), given from six months after the first dose

XBB.1.5 mRNA-CV (10 µg) for ages 5 to 11 years (blue cap)

Individuals from the age of 5 years who have not previously received any doses of COVID-19 vaccine can have a single dose of mRNA-CV (10 µg) and, if eligible, a further dose given at least three months later. See section 5.5.3 for primary course recommendations for those who are severely immunocompromised. For additional doses see section 5.5.4.

Individuals aged 5 years to 11 years who have started but not completed a primary course of any COVID-19 vaccine, including original mRNA-CV (10 µg), and have received no additional doses can be offered a dose of XBB.1.5 mRNA-CV (10 µg), given from six months after the first dose.

For children who are severely immunocompromised and eligible for three primary doses (as described in section 5.5.3), who turn 12 years after their first or second dose, continue with the same dose of paediatric vaccine (ie, mRNA-CV (10 µg)) for subsequent doses, if it is less than three months since previous dose. If it is longer than 3 months, give age-appropriate vaccine (ie. mRNA-CV (30µg)). Give an additional dose mRNA-CV (30µg) 6 months later.

XBB1.5 mRNA-CV (3 µg) for ages 6 months to 4 years (maroon)

A paediatric formulation, mRNA-CV (3µg), is available for use for certain children aged 6 months to 4 years in New Zealand. Three doses are given for the primary series individuals aged 6 months to under 5 years. Dose two is administered at least three weeks after dose one followed by dose three at least eight weeks after dose two.

The use of this vaccine is limited to young children who are at highest risk of severe disease if they were to catch COVID-19 such as those with severe immunocompromise (see section 5.5.3) or with complex and/or multiple health conditions (see the Starship website).

Children who started the primary course with the original (tozinameran) mRNA-CV (3 µg) vaccine can complete the three-dose series with XBB.1.5 mRNA-CV (3 µg).

Children who start their primary course aged under 5 years need three doses even if they turn 5 years part way through the course. For children who turn 5 years after their first or second dose, continue with the same dose of paediatric vaccine (ie, mRNA-CV (3 µg)) for subsequent primary doses, if it is less than three months since previous dose: dose two is given at least three weeks after first dose and dose three is given at least 8 weeks after previous dose. If it is longer than 3 months between their primary doses, give an age-appropriate vaccine (ie. mRNA-CV (10µg)).

The preferred vaccine for the Schedule is mRNA-CV, however, adjuvanted rCV can be offered (if not contraindicated, see section 5.6), where available, to individuals aged from 12 years who are contraindicated mRNA-CV or have experienced an adverse reaction to the first dose of mRNA-CV. It can also be offered to individuals who have declined mRNA-CV and would prefer an alternative vaccine. Individuals opting for this vaccine are recommended to discuss the benefit and potential risks of receiving this vaccine with a health professional. 

The following gives details of approved and off-label use of rCV.

• A (homologous) primary course two doses of rCV from age 12 years – no prescription is required.
• For a mixed (heterologous) primary course when a different COVID-19 vaccine dose was given previously – a further primary dose with rCV (if considered appropriate by a clinician) is an off-label use and will require prescription from an authorised provider (under regulation s25 of the Medicines Act 1981).
• Additional dose(s) following any previous COVID-19 vaccine for individuals aged 18 years or older – no prescription required.
• Additional doses are not yet approved for ages 12–17 years.

Written consent is recommended when a prescription for any doses is required.

There are no safety concerns around administering mRNA-CV or rCV to individuals who are immunocompromised and/or receiving immunosuppressive agents. As with other non-live vaccines, the antibody response to these vaccines may be reduced and protection may be suboptimal but, it is likely to be adequate to protect against severe disease. It is recommended to discuss the optimal timing for vaccination with a specialist before the vaccine appointment for those who are severely immunocompromised. Ideally, vaccination should be conducted prior to any planned immunosuppression (see section ‎4.3.6).

It is important that all household members and other close contacts of immunocompromised individuals aged from 5 years are up to date with immunisations. Close contacts aged from 16 years should also receive an additional dose at least six months after any previous doses or SARS-CoV-2 infection. For additional doses, see section ‎5.5.4.

Individuals who are severely immunocompromised

Severely immunocompromised individuals aged 5 years and over

Three primary doses of mRNA-CV (10 µg or 30 µg, as age-appropriate) are indicated for certain individuals aged from 5 years who are severely immunocompromised who are likely to have not responded adequately to the first doses (for children younger than 5 years, see note below). Serology is not recommended. A second and third primary dose is distinct from a booster dose or additional doses (for additional doses see section ‎5.5.4).

Preferably, a second dose is given eight weeks after dose one, and a third dose given a further at least eight weeks after the second dose. However, the timing also needs to consider current or planned immunosuppressive therapies. Consider vaccination during a treatment ‘holiday’ or at a nadir of immunosuppression between doses of treatment. If the period of least immunosuppression is less than eight weeks, vaccine doses can be given any time from three weeks apart.

For children who turn 12 years after their first or second dose, continue with the same dose of paediatric vaccine (ie, mRNA-CV (10 µg)) for subsequent doses, if it is less than three months since the previous dose. If the spacing is greater than 3 months, complete the primary course with an age-appropriate vaccine (ie mRNA-CV (30 µg). Give an additional dose mRNA-CV (30µg) 6 months later.

If a significant adverse reaction to mRNA-CV has occurred that contraindicates further mRNA-CV doses, then rCV may be considered for a third primary dose for those aged from 12 years (if not contraindicated) who are severely immunocompromised. This also requires prescription and written consent is recommended. It is recommended to seek advice from IMAC.

Children aged 6 months to 4 years with severe immunocompromise or complex or multiple health conditions

Note: For children aged 6 months to 4 years, three doses of mRNA-CV (3 µg) is available for those who are severely immunocompromised, including those given in Table 5.4, and for those who have complex or multiple health conditions that increase their risk from COVID-19 (see the Starship website), such as:

• chronic lung disease including bronchiectasis, cystic fibrosis, BiPAP for obstructive sleep apnoea (not asthma)
• complex congenital heart disease, acquired heart disease or congestive heart failure
• diabetes (insulin-dependent)
• chronic kidney disease (GFR <15 ml/min/1.73m²)
• severe cerebral palsy (or severe neurodisability including neuromuscular disorders)
• complex genetic, liver, metabolic disease or multiple congenital anomalies for example trisomy 21/Down Syndrome
• primary or acquired immunodeficiency, including HIV infection
• haematological malignancy and/or post-transplant (solid organ or HSCT in last 24 months)
• on immunosuppressive treatment including chemotherapy, high-dose corticosteroids, biologic agents or DMARDS.

Examples of severe immunocompromising conditions recommended three primary doses

Table 5.4 provides guidance on types of immunocompromise for which three primary doses are recommended for those aged from 5 years, and for children aged 6 months to 4 years with immunocompromise eligible for mRNA-CV (3 µg). For further information on corticosteroid indicative dosages and examples of non-corticosteroid agents considered immunosuppressive, see section below.

Vaccination should be offered regardless of an individual’s history of symptomatic or asymptomatic SARS-CoV-2 infection. As the duration of protection post infection alone, is currently unknown, vaccination is recommended. Hybrid immunity from at least three exposures to both vaccination and infection provides longer lasting protection against hospitalisation and death than vaccine or infection alone.[69] Although, there are no specific safety concerns around giving mRNA-CV to individuals with a history of symptomatic COVID-19 or asymptomatic SARS-CoV-2 infection, those who have had recent infection can experience more systemic reactogenicity after the first dose of mRNA-CV (see section 5.7.1).[78] Viral or serological testing is not required before vaccination.

For most healthy, previously vaccinated people under the age of 50 years, SARS-CoV-2 infection can boost their immunity to a level like that following a dose of vaccine and are unlikely to require further vaccine doses for at least 12 months after infection.[79]

A person aged from 5 years (or from age 6 months for special groups) who has had prior SARS-CoV-2 infection, and is at increased risk of complications, is recommended to complete the recommended course of mRNA-CV (or another COVID-19 vaccine, as available). Individuals are advised to wait 6 months after SARS-CoV-2 infection (after recovery from acute illness or from the first confirmed positive test if asymptomatic) before receiving a recommended dose of COVID-19 vaccine. Based upon clinical discretion, where the individual is at increased risk of severe disease from reinfection and has not completed the recommended doses, vaccination can be shortened to a minimum of three months after SARS-CoV-2 infection.

For all other vaccines, vaccination can commence as soon as the individual is no longer acutely unwell.

Anyone who is pregnant or planning pregnancy is encouraged to be routinely vaccinated with mRNA-CV at any stage of pregnancy. The risk of an adverse outcomes from COVID-19 infection during pregnancy is significantly higher compared to age-matched non-pregnant adults (see section ‎5.2.2).[31] International evidence from large quantities of safety surveillance has found no safety concerns with administering mRNA-CV in any stage of pregnancy including no safety concerns of the infant.[80,81,82,83,84] There is also evidence of antibody transfer in cord blood and breast milk which can offer protection to infants through passive immunity.[55,85,86,87] Infants born to those vaccinated in pregnancy have some protection from COVID-19-associated hospitalisation for up six months.[88]

Individuals who have not received any COVID-19 vaccination, are recommended to have one dose of mRNA-CV at any stage during pregnancy. Previously vaccinated individuals at increased risk of complications are recommended to receive one XBB.1.5 mRNA-CV (30µg) dose during pregnancy, at least 6 months after previous vaccination or SARS-CoV-2 infection.

People who are trying to become pregnant do not need to avoid pregnancy after receiving mRNA-CV or rCV.

Those who are unable or do not wish to receive mRNA-CV, can receive rCV in pregnancy from age 18 years. There are no known safety concerns, but due to limited experience around the use of this vaccine in pregnancy, they should discuss the suitability of rCV for them with their health professional and written consent is recommended. For further advice around eligibility and prescribing, see the Health NZ website.

Additional doses in pregnancy

XBB.1.5 mRNA-CV (30 µg) vaccine can be used in pregnancy and while breastfeeding. Pregnant women who have completed the primary course can receive an additional dose of mRNA-CV at any stage of pregnancy, regardless of the number of previous doses given (from six months after a previous last dose or SARS-CoV-2 infection, whichever is later).

If previously unvaccinated, a single dose of XBB.1.5 mRNA-CV (30 µg) can be given at any stage during the current pregnancy.

An additional dose is particularly recommended for older ages in pregnancy (usually considered those aged 35 years and older) or any age with underlying medical conditions, including hypertension, diabetes, and obesity, or who meet other eligibility criteria given above (see section ‎5.5.4).

Although there is no data available yet for the use of the XBB.1.5 mRNA-CV (30 µg) formulation in pregnancy, the safety of XBB.1.5 mRNA-CV in pregnancy is inferred from the large quantity of reassuring data from the use of the original (30µg) and bivalent (15/15µg) mRNA-CVs in pregnant people. Observational data for these vaccines show no increased risk of adverse pregnancy outcomes or increased risk of miscarriage in first trimester. The safety profile of additional doses of original mRNA COVID-19 vaccines given in pregnancy is as seen with the primary course.[89] During use in clinical trials and in real-world use from the age of 12 years, no clinically meaningful difference in safety profiles has been shown between the monovalent and the bivalent mRNA COVID-19 vaccines. There is no theoretically plausible reason for there to be any increased risk in pregnancy because the differences between these vaccine formulations are confined to mRNA spike protein sequences.

Although an mRNA-CV is the preferred vaccine, rCV can be used for those aged from 18 years in pregnancy following discussion with their health professional as this use may require a prescription, and written consent is recommended. For further advice around eligibility and prescribing, see the Health NZ website.

As with all schedule vaccines, there are no safety concerns about giving mRNA-CV to those lactating. There is limited data to date around the use of adjuvanted rCV in lactation.

It is highly recommended that all eligible adults including the frail and elderly with comorbidities are offered vaccination against COVID-19, if there are no contraindications to its administration (see section 5.6.1), to provide protection for the individual as well as their community, especially when living in residential care facilities. 

It is recommended that all previously unvaccinated individuals from age 5 years to receive one dose of mRNA-CV (30 µg or 10 µg, as age appropriate). Pre-existing cardiac conditions, in general, are not regarded as precautions or contraindications to vaccination. This includes pre-existing rheumatic heart disease. Note that many cardiac conditions increase the risk from COVID-19 infection.

Individuals aged from 5 years with a history of pericarditis or myocarditis, unrelated to mRNA-CV, can have the vaccine once the condition is completely resolved, (ie, no symptoms and no evidence of ongoing cardiac inflammation).

Infants and young children aged from 6 months to 4 years with complex congenital heart disease, acquired heart disease or congestive heart failure are recommended to received three doses of mRNA-CV (3 µg), dose two given at least three weeks after dose one and dose three given at least eight weeks later. An additional dose can be considered at 6 months after the previous vaccine dose or SARS-CoV-2 infection. For young children with a history of inflammatory heart disease, discuss with cardiologist/specialist paediatrician.

For those with a history of myocarditis and pericarditis related to mRNA-CV, seek specialist immunisation advice on a case-by-case basis to consider an appropriate alternative vaccine (eg rCV from age 18 years as an additional dose) or no further vaccination, and timing of any further doses. See section 5.6.2 for those who have myocarditis associated with mRNA-CV.

Individuals from age 6 months who have undergone haematopoietic stem cell transplantation since their first course can be revaccinated with a three-dose primary course of a COVID-19 vaccine, plus additional doses as age appropriate (preferably with age-appropriate mRNA-CV).

Based on clinical discretion, if all scheduled doses have been completed prior to commencement of chemotherapy or solid organ transplant, a single further dose of mRNA-CV can be given.

Vaccination with mRNA-CV or rCV is contraindicated for individuals with a history of anaphylaxis to any component or previous dose the same vaccine.

A definite history of immediate allergic reaction to any other product is considered as a precaution but not a contraindication to vaccination with COVID-19 vaccines (mRNA-CV or rCV). A slightly increased risk of a severe allergic response in individuals who have had a previous anaphylaxis-type reaction needs to be balanced against the risk of SARS-CoV-2 exposure and severe COVID‑19. These individuals can still receive a COVID-19 vaccines, if not contraindicated, and observation extended to 30 minutes after vaccination in health care settings, where anaphylaxis can be immediately treated with adrenaline.

Myocarditis or pericarditis

If myocarditis, myopericarditis or pericarditis occurs after a dose of mRNA-CV or rCV, defer further doses of COVID-19 vaccination. Seek specialist immunisation advice, on a case-by-case basis, to consider an appropriate alternative vaccine or no further vaccination, and about timing for further doses. Vaccination is not recommended for anyone with current active cardiac inflammation.

The risk of myocarditis following vaccination is not thought to be greater in children aged 6 months to 4 years than any other group, acknowledging that background rates of myocarditis from any cause in infants (aged under 1 year) are generally higher than in older children. There is no current evidence of a safety concern with this vaccine in young children or infants, overall.

Pregnancy

The preferred vaccine to be given in pregnancy is mRNA-CV. Those who are pregnant are advised to discuss the benefit and potential risks of receiving rCV in pregnancy with their health professional. There are no safety concerns should it be given inadvertently in pregnancy.

mRNA COVID 19 vaccine – Comirnaty (Pfizer/BioNTech)

Commonly reported responses to mRNA-CV (30 µg) are injection-site pain, headache, dizziness and fatigue; other responses included muscle aches, feeling generally unwell, chills, fever, chest discomfort, joint pain, nausea and axillar lymph node swelling. These occurred most often after dose two and in younger adults (aged 18–55 years), and within one or two days of vaccination. Most are mild or moderate in severity and are self-limiting.[48,83] According to Australian AusVaxSafety active surveillance data, the responses to XBB.1.5 mRNA-CV, given as a single primary dose or as an additional dose, are similar or milder than the previous mRNA-CV vaccines.[90] No new adverse reactions have been identified in clinical trials and real-world usage.[91] Analgesia, such as paracetamol or ibuprofen (as appropriate), can be taken for pain and discomfort following vaccination. It is advisable to limit vigorous exercise if feeling unwell.

Responses to the paediatric formulation mRNA-CV (10 µg) in children aged 5–11 years are similar to those seen for the adult formulation mRNA-CV (30 µg) in those age 16–25 years. During clinical trials, reactions were generally mild to moderate and short-lived. Pain at injection site was commonly reported (by over 70 percent) after dose one and two. Overall fewer children reported systemic reactions than seen after the 30 µg dose in adults, with fever, fatigue, headache, chills and muscle ache as the most common and more frequent after the second dose.[46] These responses were mirrored in reports to VAERS and V-safe after 8.7 million doses given routinely to children in the US.[92] As with adults, the responses to paediatric XBB.1.5 mRNA-CV, given as a single primary dose or as an additional dose, are expected to be similar to the earlier mRNA-CV.

In clinical trials for paediatric mRNA-CV (3 µg), the most frequent responses seen in infants (aged 6–23 months) were irritability, decreased appetite, injection-site tenderness and redness, and fever; and in children aged 2–4 years, injection-site pain and redness, fatigue and fever. Less common responses included lymphadenopathy, diarrhoea, vomiting and nausea. Consistent with the clinical trial, systemic reactions were more frequently reported to V-safe in the US for infants (ages 6 months – 2 years) than those aged 3–5 years.[93]

See chapter 2 (section 2.3.3) for immunisation-stress related responses (ISRR).

Adjuvanted recombinant COVID-19 vaccine – Nuvaxovid (Novavax)

The most reported responses to rCV in clinical trials were injection-site tenderness and pain, headache, fatigue, myalgia, malaise, arthralgia, nausea and vomiting. These reactions were more common after dose two, lasting for one to three days, and occurred at higher incidence in younger age groups (less than 65 years).[61]

Breast screening and CT scans

Transient unilateral axillary adenopathy, a known response to vaccination, was particularly noted following vaccination with mRNA-CV due to the scale of the roll-out and age groups being immunised. Early estimates suggest that 12–16 percent of vaccine recipients experience axillary adenopathy after vaccination with mRNA-CV, starting one or two days after vaccination and which can persist for several weeks.[94, 95] Lymphadenopathy has also been commonly reported after additional doses of mRNA-CV.[96]

When attending breast screening appointments, including MRI scans and mammography, it is recommended that individuals advise the radiographer or doctor that they have received a COVID-19 vaccine recently. It is advised to monitor any lymph node changes that persist for longer than six weeks after vaccination.[94]

Likewise, individuals undergoing FDG PET/CT or MRI scans for cancer screening are advised to inform the radiologist or their oncologist that they have been recently vaccinated, or, if possible, to have COVID-19 vaccination at least two weeks before a scheduled scan or as soon as possible afterwards. Treatment should not be delayed.

Adverse events following immunisation (AEFIs) with the COVID-19 vaccines are being closely monitored during clinical trials and by post marketing surveillance. A dedicated COVID-19 vaccine AEFI reporting tool is available online from CARM (see section 1.6.3). Medsafe reports weekly on the AEFI reported to CARM after COVID-19 vaccinations (see the Medsafe website).

A list of adverse events of special interest (AESIs), including those previously associated with immunisation in general and with the individual vaccine platforms, was created by Safety Platform for Emergency Vaccines (SPEAC) in collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) and based on existing and new Brighton Collaboration case definitions. For further information, see the Brighton Collaboration website. Global pharmacovigilance and active safety monitoring systems continue to watch for both AESI and unexpected AEFI.

mRNA COVID 19 vaccine – Comirnaty (Pfizer/BioNTech)

Overall, no AESI signals were detected by the Vaccine Safety Datalink in the US up to 21 days after vaccination, following the administration of over 13 million doses of mRNA-CV (Comirnaty), however, subgroup analyses did find mRNA-CV to be associated with a slight increase in myocarditis and pericarditis in younger people (aged under 30 years).[97, 98]

Preliminary phase II/III clinical trial safety data reported lymphadenopathy in 64 (0.3%) vaccine recipients and six (<0.1%) placebo recipients (follow-up of up to 14 weeks after second dose of a subset of 18,860 participants who received at least one dose of mRNA-CV). Four vaccine-related adverse events were recorded (namely, shoulder injury related to vaccine administration, lymphadenopathy local to injection site, paroxysmal ventricular arrhythmia and right leg paraesthesia). No deaths were related to either the vaccine or the placebo.[48] During clinical trial follow-up to 1 February 2021, acute peripheral facial paralysis (Bell’s palsy) was reported by four vaccinated participants and none in the placebo group.[99] No safety signal has been detected for this condition as an AESI,[100] and safety monitoring is ongoing.

No vaccine-related severe adverse events were seen during the phase II/III clinical trial of mRNA-CV (10 µg) and mRNA-CV (3 g). In 1,518 children aged 5–11 years, lymphadenopathy was reported in ten (0.9 percent) of mRNA-CV (10 µg) recipients. Rashes, with no consistent pattern, considered related to the vaccination were observed in four participants; these were mild and self-limiting with typical onset seven or more days after vaccination. No differences were apparent in vaccine safety between the children who had baseline evidence of previous SARS-CoV-2 infection.[46] Following administration of approximately 8.7 million doses of mRNA-CV (10 µg) in children aged 5–11 years in the US, the majority of reports to VAERS (97.6 percent) were non-serious and 2.4 percent were serious. The most common non-serious reports were due to vaccine administration errors. Of the serious reports, 11 verified cases of myocarditis were reported to VAERS but no chart-confirmed myocarditis cases were reported through the Vaccine Safety Datalink in this age group.[92] Post-licensure surveillance is ongoing internationally.

Bivalent mRNA and XBB.1.5 COVID-19 vaccines

Safety monitoring in the US was evaluated following of use bivalent mRNA-CV as a booster dose (approximately 14.4 million doses bivalent Comirnaty and 8.2 million doses of bivalent Moderna) given to those who had received at least two doses of monovalent original mRNA-CV.[91] Of the 5,542 VAERS reports, 34% of events were vaccine administration and handling errors and 95% non-serious AEFI. V-safe reports, from almost 211,959 participants aged at least 12 years who received age-appropriate bivalent booster doses, were consistent with those reported following monovalent booster doses. Most people were receiving their fourth or fifth COVID-19 vaccine dose and 98.3 percent received influenza vaccine at the same visit. Adverse events were less common and less serious than the health impacts associated with COVID-19 illness.[91]

A Danish data linking study, covering a cohort of over one million adults aged 65 years and over (mean 74.7 years ± 7.4 years), reported no increased risk for 28 predetermined adverse events were observed within 28 days following XBB.1.5 mRNA-CV given as a fifth COVID-19 vaccine dose.[101] For example, incidence rate ratio of hospital contact was 0.96 (95% CI 0.87-1.07) for an ischaemic cardiac event, 0.87 (0.79-0.96) for cerebral infarction and 0.60 (0.14-2.66) for myocarditis.[101]

Myocarditis and pericarditis

A small increase in incidence of myocarditis, myopericarditis and pericarditis has been observed following the second dose of mRNA-CV vaccination (40.6 cases per million doses in young males and 4.2 cases per million in young females, aged 12–29 years, decreasing to 2.4 and 1.0 per million, respectively, in men and women aged over 30 years).[102] Very rarely, myocarditis has also been report in boys aged 5–11 years after dose two in the US (reporting rate of 2.2 cases per million doses).[103] Most cases occur within 14 days of vaccination typically with full recovery after standard treatment and rest.[104, 105] A review of clinical records in the US observed the median time to onset for myocarditis was 3.5 days (interquartile range 3.0–10.8 days) after vaccination and a median of 20 days (range 6.0–41 days) for pericarditis.[105] Wider spacing between doses (ie, eight weeks) has been shown to significantly lower the risk of myocarditis in young adults in Canada.[106] Following 22.6 million doses of bivalent mRNA-CV given to individuals aged from 12 years in the US, three out of five cases of myocarditis and four cases of pericarditis reported to VAERS were medically verified. These early data confirm that myocarditis and pericarditis post vaccine dose is an extremely rare event and suggests that this rate is the same or lower than after the primary doses.[91]

Myocarditis and pericarditis are uncommon conditions considered to be associated with viral infection, including COVID-19. Recently vaccinated individuals should seek immediate medical attention if they experience new onset of (acute and persisting) chest pain, shortness of breath or arrhythmia (palpitations). Diagnosis is based on elevated troponin, C-reactive protein and electrocardiogram and/or MRI findings. Report all suspected cases to CARM as Medsafe continues to monitor this AEFI closely. Defer further doses of mRNA-CV if myocarditis or pericarditis occurs after vaccination. Seek specialist immunisation advice, on a case-by-case basis, to consider an appropriate alternative vaccination option, and timing for further doses (see section 5.6.2).

Anaphylaxis

Following approval for use in the US, the VAERS detected 47 cases of anaphylaxis after administration of just under ten million doses (around five cases per million doses) mRNA-CV (Pfizer/BioNTech). The median interval to symptom onset was ten minutes (range <1–1140 minutes), almost 90 percent occurred within 30 minutes of vaccination.[107] All were successfully treated with adrenaline. See section 5.6 for contraindications and precautions.

A placebo-controlled trial evaluated the recurrence of systemic allergic reactions after a second or third dose of mRNA-CV in individuals who reported anaphylactic reactions after previous dose.[108] It found that immunisation stress-related (ISRR) responses were significantly more common (more than five times higher), including in the placebo group, than recurrent serious allergic reactions following revaccination. Increased levels of anxiety prior to vaccination were a risk factor for ISRR.[108]

See chapter 2 (section 2.3.3) for immunisation-stress related responses.

History of Guillain-Barré Syndrome

There is no evidence of a higher rate of reporting of Guillain-Barré syndrome (GBS) following COVID-19 vaccination in individuals who have previously had GBS. Vaccination with mRNA-CV is preferred.

Adjuvanted recombinant COVID-19 vaccine – Nuvaxovid (Novavax)

Uncommon AEFI reported during clinical trials were lymphadenopathy, hypertension (observed in 1 percent of older adults for three days following vaccination), rash and injection site pruritus. One case of myocarditis was observed in a clinical trial occurring three days after second dose was deemed by the independent safety monitoring committee to most likely be viral myocarditis. No episodes of anaphylaxis were reported.[61] Three cases of myocarditis or myopericarditis and two cases of pericarditis were reported during two clinical trials (one case in placebo group) and in two cross-over studies. Although a causal relationship to the vaccine could not be confirmed, the European Medicines Agency listed heart inflammation as a potential risk.[96]

In a clinical trial, when rCV was given as a second dose after a first dose of mRNA-CV, similar systemic responses were observed to those given mRNA-CV as a second dose and local reactions were generally less frequent.[109]

A slightly increased incidence of local adverse events such as injection site tenderness and pain were reported during a clinical trial of rCV given concurrently with seasonal influenza vaccine (65 percent rCV plus influenza vs 53 percent for rCV alone of participants reported tenderness). This component of a randomised, placebo controlled clinical trial included 201 people who received rCV and QIV concurrently and 16 participants aged 65 years or older who received adjuvanted TIV.[59]

1. V'Kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews: Microbiology, 2021. 19(3): p. 155-170.
2. Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 2020. 181(2): p. 281-292 e6.
3. World Health Organization. 2021 Tracking SARS-CoV-2 variants. WHO; 2021 [updated 13 December 2021]; URL: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. (accessed 17 December)
4. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe, 2021. 2(1): p. e13-e22.
5. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA, 2020. 323(14): p. 1406-07.
6. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infectious Diseases, 2020. 20(6): p. 656-7.
7. Piccoli L, Ferrari P, Piumatti G, et al. Risk assessment and seroprevalence of SARS-CoV-2 infetion in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health - Europe, 2021. 1.
8. McGregor R, Craigie A, Jack S, et al. The persistence of neutralising antibodies up to 11 months after SARS CoV-2 infection in the southern region of New Zealand. New Zealand Medical Journal, 2022. 135(1550): p. 162-166.
9. Whitcombe AL, McGregor R, Craigie A, et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clin Transl Immunology, 2021. 10(3): p. e1261.
10. Lewis N, Chambers LC, Chu HT, et al. Effectiveness associated with vaccination after COVID-19 recovery in preventing reinfection. JAMA Netw Open, 2022. 5(7): p. e2223917-e2223917.
11. Nordstrom P, Ballin M ,Nordstrom A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infectious Diseases, 2022. 22(6): p. 781-790.
12. World Health Organization. 2021 Interim statement on COVID-19 vaccination for children and adolescents. WHO; 2021 [updated 29 November 2021]; URL: https://www.who.int/news/item/24-11-2021-interim-statement-on-covid-19-vaccination-for-children-and-adolescents. (accessed 2021 December 14)
13. Powell AA, Dowell AC, Moss P,Ladhani SN. Current state of COVID-19 in children: 4 years on. Journal of Infection, 2024. 88(5): p. 106134.
14. Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: A systematic review and meta-analysis. EClinicalMedicine, 2021. 41.
15. Tsankov BK, Allaire JM, Irvine MA, et al. Severe COVID-19 infection and pediatric comorbidities: A systematic review and meta-analysis. International Journal of Infectious Diseases, 2021. 103: p. 246-256.
16. Ministry of Health. 2021 Regional Data Explorer 2017-2020: New Zealand Health Survey. URL: https://www.health.govt.nz/publication/regional-results-2017-2020-new-zealand-health-survey. (accessed 14 December 2021)
17. Murray S. 2019 The state of wellbeing and equality for disabled people, their families, and whānau. URL: https://apo.org.au/node/270566. (accessed 14 December 2021)
18. Carter MJ, Shankar-Hari M ,Tibby SM. Paediatric inflammatory multisystem syndrome temporally-associated with SARS-CoV-2 infection: an overview. Intensive Care Medicine, 2021. 47(1): p. 90-93.
19. Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infectious Diseases, 2020. 20(11): p. e276-e288.
20. Reddy RK, Charles WN, Sklavounos A, et al. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. Journal of Medical Virology, 2021. 93(2): p. 1045-1056.
21. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol, 2020. 8(10): p. 813-822.
22. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature, 2020. 584(7821): p. 430-436.
23. Maze M, Williman J, Best E, et al. 2023 Clinical and Demographic Predictors of COVID-19 Severity in New Zealand. . Christchurch, New Zealand. (accessed
24. Kotlar B, Gerson E, Petrillo S, et al. The impact of the COVID-19 pandemic on maternal and perinatal health: a scoping review. Reprod Health, 2021. 18(1): p. 10.
25. Mullins E, Hudak ML, Banerjee J, et al. Pregnancy and neonatal outcomes of COVID-19: co-reporting of common outcomes from PAN-COVID and AAP SONPM registries. Ultrasound in Obstetrics and Gynecology, 2021. 57(4): p. 573-581.
26. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID Multinational Cohort Study. JAMA Pediatr, 2021. 175(8): p. 817-826.
27. Vousden N, Bunch K, Morris E, et al. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS). PloS One, 2021. 16(5): p. e0251123.
28. Carlson J, Simeone RM, Ellington S, et al. Pre-Delta, Delta, and Omicron periods of the Coronavirus Disease 2019 (COVID-19) pandemic and health outcomes during delivery hospitalization. Obstetrics and Gynecology, 2024. 143(1): p. 131-138.
29. Engjom HM, Ramakrishnan R, Vousden N, et al. Severity of maternal SARS-CoV-2 infection and perinatal outcomes of women admitted to hospital during the omicron variant dominant period using UK Obstetric Surveillance System data: prospective, national cohort study. BMJ Medicine, 2022. 1(1): p. e000190.
30. Villar J, Soto Conti CP, Gunier RB, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet, 2023. 401(10375): p. 447-457.
31. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ, 2020. 370: p. m3320.
32. Adhikari EH, Moreno W, Zofkie AC, et al. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus-2 infection. JAMA Netw Open, 2020. 3(11): p. e2029256.
33. Liguoro I, Pilotto C, Bonanni M, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur. J. Pediatrics, 2020. 179(7): p. 1029-1046.
34. Greenhalgh T, Knight M, A'Court C, et al. Management of post-acute covid-19 in primary care. BMJ, 2020. 370: p. m3026.
35. Sivan M ,Taylor S. NICE guideline on long COVID. BMJ, 2020. 371: p. m4938.
36. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Medicine, 2021. 27(4): p. 626-631.
37. Del Rio C, Collins LF ,Malani P. Long-term health consequences of COVID-19. JAMA, 2020. 324(17): p. 1723-1724.
38. World Health Organization. 2023 A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus, 16 February 2023. URL: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post-COVID-19-condition-CA-Clinical-case-definition-2023-1. (accessed 5 April 2024)
39. World Health Organization. 2023 From emergency response to long-term COVID-19 disease management: sustaining gains made during the COVID-19 pandemic. WHO; 2023 [updated 3 May 2023]; WHO/WHE/SPP/2023.1:[URL: https://www.who.int/publications/i/item/WHO-WHE-SPP-2023.1. (accessed February 7)
40. Geoghegan JL, Ren X, Storey M, et al. Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand. Nat Commun, 2020. 11(1): p. 6351.
41. Public Health Agency. 2022 COVID-19 mortality in Aotearoa New Zealand: Inequities in risk. . Wellington. URL: https://www.health.govt.nz/publication/covid-19-mortality-aotearoa-new-zealand-inequities-risk. (accessed 1 November 2022)
42. Callaway E. The race for coronavirus vaccines: a graphical guide. Nature, 2020. 580(7805): p. 576-7.
43. Flanagan KL, Best E, Crawford NW, et al. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Frontiers in Immunology, 2020. 11: p. 579250.
44. Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine, 2020. 383(25): p. 2439-2450.
45. Frenck RW, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. New England Journal of Medicine, 2021. 385(3): p. 239-250.
46. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. New England Journal of Medicine, 2021. 386(1): p. 35-46.
47. Fleming-Dutra KE, Wallace M, Moulia DL, et al. Interim recommendations of the Advisory Committee on Immunization Practices for use of Moderna and Pfizer-BioNTech COVID-19 vaccines in children aged 6 months–5 years — United States, June 2022. MMWR. Morbidity and Mortality Weekly Report, 2022. 71(26): p. 859-868.
48. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine, 2020. 383(27): p. 2603-2615.
49. Vaccines and Related Biological Products Advisory Committee Meeting. 2022 FDA briefing document. EUA amendment request for Pfizer-BioNTech COVID-19 vaccine for use in children 6 months through 4 years of age. URL: https://www.fda.gov/media/159195/download. (accessed 2 February 2023)
50. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. New England Journal of Medicine, 2021. 384(15): p. 1412-1423.
51. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021. 385(7): p. 585-594.
52. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ, 2021. 373: p. n1088.
53. Birol Ilter P, Prasad S, Berkkan M, et al. Clinical severity of SARS-CoV-2 infection among vaccinated and unvaccinated pregnancies during the Omicron wave. Ultrasound in Obstetrics and Gynecology, 2022. 59(4): p. 560-562.
54. Intensive Care National Audit and Research Centre (ICNARC). 2022 ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland, 8 July 2022. London, UK. URL: https://www.icnarc.org/our-audit/audits/cmp/reports. (accessed 21 July 2022)
55. Kugelman N, Nahshon C, Shaked-Mishan P, et al. Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2022. 274: p. 148-154.
56. Rahmati M, Yon DK, Lee SW, et al. Effects of COVID‐19 vaccination during pregnancy on SARS‐CoV‐2 infection and maternal and neonatal outcomes: A systematic review and meta‐analysis. Reviews in Medical Virology, 2023. 33(3).
57. Zerbo O, Ray GT, Fireman B, et al. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. Nat Commun, 2023. 14(1): p. 894.
58. Zerbo O, Ray GT, Fireman B, et al. Effectiveness of COVID-19 vaccination during pregnancy by circulating viral variant. AJOG Glob Rep, 2023. 3(4): p. 100264.
59. Toback S, Galiza E, Cosgrove C, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021.
60. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. New England Journal of Medicine, 2022. 386: p. 531-543.
61. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine, 2021. 385(13): p. 1172-1183.
62. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of the NVX-CoV2373 COVID-19 vaccine at completion of the placebo-controlled phase of a randomized controlled trial. Clinical Infectious Diseases, 2022.
63. Andrews N, Stowe J, Kirsebom F, et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv, 2021 (preprint): p. 2021.12.14.21267615.
64. Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. medRxiv, 2022 (preprint): p. 2021.12.30.21268565.
65. Mallory RM, Formica N, Pfeiffer S, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 2022.
66. Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 2022.
67. Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature, 2022. 603(7901): p. 493-496.
68. Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by COVID-19 vaccines. New England Journal of Medicine, 2022.
69. Wu S, Li Y, Baral S, et al. Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada. PloS One, 2024. 19(2): p. e0299304.
70. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature, 2021.
71. Lin DY, Xu Y, Gu Y, et al. Effectiveness of bivalent boosters against severe Omicron infection. New England Journal of Medicine, 2023. 388(8): p. 764-766.
72. Surie D, DeCuir J, Zhu Y, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022. MMWR: Morbidity and Mortality Weekly Report, 2022. 71(5152): p. 1625-1630.
73. Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. MMWR: Morbidity and Mortality Weekly Report, 2022. 71(5152): p. 1616-1624.
74. Huiberts AJ, Hoeve CE, De Gier B, et al. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Eurosurveillance, 2024. 29(10).
75. van Werkhoven CH, Valk AW, Smagge B, et al. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. Euro Surveillance, 2024. 29(1).
76. Link-Gelles R, Ciesla AA, Mak J, et al. Early estimates of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection attributable to co-circulating omicron variants among immunocompetent adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. MMWR: Morbidity and Mortality Weekly Report, 2024. 73(4): p. 77-83.
77. Wang Q, Guo Y, Bowen A, et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe, 2024.
78. Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infectious Diseases, 2021.
79. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases, 2023. 23(5): p. 556-567.
80. Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccination during pregnancy: coverage and safety. American Journal of Obstetrics and Gynecology, 2021.
81. Lipkind HS, Vazquez-Benitez G, DeSilva M, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth - Eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. MMWR: Morbidity and Mortality Weekly Report, 2022. 71(1): p. 26-30.
82. Sadarangani M, Soe P, Shulha HP, et al. Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study. The Lancet Infectious Diseases.
83. Shimbabukuro T ,CDC-COVID-19 Vaccine Task Force. 2021 COVID-19 vaccine safety update. . (ACIP) ACoIP. URL: https://www.cdc.gov/vaccines/acip/meetings/slides-2021-1-27-21.html. (accessed 5 February 2021)
84. Faherty EAG, Wilkins KJ, Jones S, et al. Pregnancy outcomes among pregnant persons after COVID-19 vaccination: Assessing vaccine safety in retrospective cohort analysis of U.S. National COVID Cohort Collaborative (N3C). Vaccines (Basel), 2024. 12(3): p. 289.
85. Perl SH, Uzan-Yulzari A, Klainer H, et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA, 2021. 325(19): p. 2013-2014.
86. Prabhu M, Murphy EA, Sukhu AC, et al. Antibody response to Coronavirus Disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood. Obstetrics and Gynecology, 2021. 138(2): p. 278-280.
87. Rottenstreich A, Zarbiv G, Oiknine-Djian E, et al. Efficient maternofetal transplacental transfer of anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies After antenatal SARS-CoV-2 BNT162b2 messenger RNA vaccination. Clin Inf Dis, 2021. 73(10): p. 1909-1912.
88. Halasa N, Olson S, Staat M,al. e. Effectiveness of maternal vaccination with mRNA COVID-19 vaccine during pregnancy against COVID-19–associated hospitalization in infants aged <6 months — 17 States, July 2021–January 2022. MMWR: Morbidity and Mortality Weekly Report, 2022. 71(Early Release).
89. Moro PL, Olson CK, Zhang B, et al. Safety of booster doses of Coronavirus Disease 2019 (COVID-19) vaccine in pregnancy in the Vaccine Adverse Event Reporting System. Obstetrics and Gynecology, 2022. 140(3): p. 421-427.
90. AusVaxSafety. Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccine safety data – all participants. [updated 15 April 2024]; URL: https://ausvaxsafety.org.au/covid-19-vaccines/pfizer-monovalent-omicron-xbb15-covid-19-vaccine-safety-data-all-participants. (accessed 2 May 2024)
91. Hause AM, Marquez P, Zhang B, et al. Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged ≥12 years - United States, August 31-October 23, 2022. MMWR: Morbidity and Mortality Weekly Report, 2022. 71(44): p. 1401-1406.
92. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 years - United States, November 3-December 19, 2021. MMWR: Morbidity and Mortality Weekly Report, 2021. 70(5152): p. 1755-1760.
93. Hause AM, Marquez P, Zhang B, et al. COVID-19 mRNA vaccine safety among children aged 6 months-5 years - United States, June 18, 2022-August 21, 2022. MMWR: Morbidity and Mortality Weekly Report, 2022. 71(35): p. 1115-1120.
94. Edmonds CE, Zuckerman SP ,Conant EF. Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of coronavirus disease (COVID-19) vaccination. AJR: American Journal of Roentgenology, 2021.
95. Garreffa E, Hamad A, O'Sullivan CC, et al. Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care. European Journal of Cancer, 2021. 159: p. 38-51.
96. Medsafe. 2022 Adverse events following immunisation with COVID-19 vaccines: Safety Report #40 – 31 January 2022. online. URL: https://www.medsafe.govt.nz/COVID-19/safety-report-40.asp. (accessed 25 February 2022)
97. Klein N. 2021 Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink: myocarditis and anaphylaxis. Advisory Committee on Immunization Practices (ACIP). URL: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/04-COVID-Klein-508.pdf. (accessed 20 September 2021)
98. Gargano J, Wallace M, Hadler S, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from Advisory Committee on Immunization Practices - United States, June 2021. MMWR: Morbidity and Mortality Weekly Report, 2021. 70(27): p. 977-982.
99. Pfizer New Zealand. 2021 New Zealand Datasheet: Comirnaty COVID-19 vaccine. Medsafe. URL: https://www.medsafe.govt.nz/profs/Datasheet/c/comirnatyinj.pdf. (accessed 10 November 2021)
100. Renoud L, Khouri C, Revol B, et al. Association of facial paralysis with mRNA COVID-19 vaccines: A disproportionality analysis using the World Health Organization pharmacovigilance database. JAMA Intern Med, 2021. 181(9): p. 1243-1245.
101. Andersson NW, Thiesson EM ,Hviid A. Adverse Events After XBB.1.5-Containing COVID-19 mRNA Vaccines. JAMA, 2024. 331(12): p. 1057-1059.
102. World Health Organization. 2021 COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines.: WHO; 2021 [updated 9 July 2021]; URL: https://www.who.int/news/item/09-07-2021-gacvs-guidance-myocarditis-pericarditis-covid-19-mrna-vaccines. (accessed 12 July 2021)
103. Hause AM, Shay DK, Klein NP, et al. Safety of COVID-19 vaccination in United States children ages 5 to 11 years. Pediatrics, 2022. 150(2).
104. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. New England Journal of Medicine, 2021. 385(23): p. 2140-2149.
105. Diaz GA, Parsons GT, Gering SK, et al. 2021. Myocarditis and pericarditis after vaccination for COVID-19. JAMA. DOI: 10.1001/jama.2021.13443 (accessed 16 August 2021)
106. Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open, 2022. 5(6): p. e2218505.
107. Shimabukuro TT, Cole M ,Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA, 2021. 325(11): p. 1101-1102.
108. Khalid MB, Zektser E, Chu E, et al. A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination. Journal of Allergy and Clinical Immunology, 2024.
109. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, 2022. 399(10319): p. 36-49.